175 related articles for article (PubMed ID: 25519475)
21. [Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre].
Zhou JY; He GS; Wu DP; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Miao M; Xue SL; Wang Y
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3185-8. PubMed ID: 24405537
[TBL] [Abstract][Full Text] [Related]
22. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
23. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
24. Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.
Hiramoto N; Kurosawa S; Tajima K; Okinaka K; Tada K; Kobayashi Y; Shinohara A; Inoue Y; Ueda R; Tanaka T; Kim SW; Yamashita T; Heike Y; Fukuda T
Eur J Haematol; 2014 Feb; 92(2):137-46. PubMed ID: 24127668
[TBL] [Abstract][Full Text] [Related]
25. Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC.
Caulier A; Drumez E; Gauthier J; Robin M; Blaise D; Beguin Y; Michallet M; Chevallier P; Bay JO; Vigouroux S; Desbrosses Y; Cornillon J; Nguyen S; Dauriac C; de Latour RP; Lioure B; Rohrlich PS; Carré M; Bourhis JH; Huynh A; Suarez F; Garnier F; Duhamel A; Yakoub-Agha I
Curr Res Transl Med; 2019 Feb; 67(1):8-15. PubMed ID: 30206045
[TBL] [Abstract][Full Text] [Related]
26. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.
Neukirchen J; Lauseker M; Blum S; Giagounidis A; Lübbert M; Martino S; Siragusa S; Schlenk RF; Platzbecker U; Hofmann WK; Götze K; Palumbo GA; Magrin S; Kündgen A; Aul C; Hildebrandt B; Hasford J; Kobbe G; Haas R; Germing U
Leuk Res; 2014 Jan; 38(1):57-64. PubMed ID: 24238640
[TBL] [Abstract][Full Text] [Related]
27. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
28. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
29. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
30. Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes.
Kröger N
Semin Hematol; 2017 Jul; 54(3):154-158. PubMed ID: 28958289
[TBL] [Abstract][Full Text] [Related]
31. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.
Woodard P; Barfield R; Hale G; Horwitz E; Leung W; Ribeiro R; Rubnitz J; Srivistava DK; Tong X; Yusuf U; Raimondi S; Pui CH; Handgretinger R; Cunningham JM
Pediatr Blood Cancer; 2006 Dec; 47(7):931-5. PubMed ID: 16155933
[TBL] [Abstract][Full Text] [Related]
32. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry.
del Cañizo MC; Martínez C; Conde E; Vallejo C; Brunet S; Sanz G; Mateos MV;
Bone Marrow Transplant; 2003 Nov; 32(10):987-92. PubMed ID: 14595386
[TBL] [Abstract][Full Text] [Related]
33. Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype.
Wudhikarn K; Van Rheeden R; Leopold C; Rattanaumpawan P; Gingrich R; de Magalhaes Silverman M
Eur J Haematol; 2012 Oct; 89(4):294-301. PubMed ID: 22762733
[TBL] [Abstract][Full Text] [Related]
34. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.
Appelbaum FR; Anderson J
Leukemia; 1998 Sep; 12 Suppl 1():S25-9. PubMed ID: 9777891
[TBL] [Abstract][Full Text] [Related]
36. Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
Ustun C; Trottier BJ; Sachs Z; DeFor TE; Shune L; Courville EL; Holtan SG; Dolan M; Weisdorf DJ; Warlick ED
Biol Blood Marrow Transplant; 2015 May; 21(5):866-72. PubMed ID: 25620751
[TBL] [Abstract][Full Text] [Related]
37. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
[TBL] [Abstract][Full Text] [Related]
38. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
39. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
40. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome.
Nakai K; Kanda Y; Fukuhara S; Sakamaki H; Okamoto S; Kodera Y; Tanosaki R; Takahashi S; Matsushima T; Atsuta Y; Hamajima N; Kasai M; Kato S
Leukemia; 2005 Mar; 19(3):396-401. PubMed ID: 15674354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
